Johnson & Johnson Sues To Stop Generic Risperdal

Law360, New York (June 30, 2006, 12:00 AM EDT) -- A subsidiary of Johnson & Johnson has filed a federal patent infringement lawsuit in an attempt to thwart a Canadian pharmaceutical company’s efforts to introduce a generic version of Risperdal, the latest in a series of suits filed by J&J to protect the market for its blockbuster antipsychotic drug.

The lawsuit, filed on behalf Belgian J&J subsidiary Janssen Pharmaceutica N.V. and its New Jersey-based unit, Jansen L.P., charges Apotex Inc. with infringing on U.S. Patent Number 4,804,663. That patent covers risperidone, which is marketed by Janssen...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.